Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2024

01-05-2024 | Filgrastim | News item

G-CSF-related myelodysplastic syndrome and acute myeloid leukemia

Published in: Reactions Weekly | Issue 1/2024

Login to get access

Excerpt

The Japanese Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency have announced that product information for granulocyte colony-stimulating factors (G-CSF) including filgrastim, pegfilgrastim and lenograstim will be updated to include the risk of myelodysplastic syndrome and acute myeloid leukaemia (AML), reports WHO in WHO Pharmaceutical Newsletter No. 2, 2024. …
Literature
Metadata
Title
G-CSF-related myelodysplastic syndrome and acute myeloid leukemia
Publication date
01-05-2024
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-57898-6

Other articles of this Issue 1/2024

Reactions Weekly 1/2024 Go to the issue

Case report

Ruxolitinib

Case report

Alendronic-acid/sarilumab

Case report

Oritavancin

Case report

Carboplatin/Pembrolizumab/Pemetrexed

Case report

Welgenaleucel

Case report

Ipilimumab/Nivolumab